Hims & Hers (HIMS) Q2 2026 earnings review
Massive Top-Line Breakout Masked by Margin Compression and Legal Costs
Hims & Hers delivered a blowout quarter for revenue, growing 38% YoY to $753.2 million, driven by the close of the Eucalyptus acquisition and a strategic pivot to higher-priced branded weight-loss drugs. However, this growth came at a steep cost to profitability. Gross margins plunged 12 points YoY to 64%, and the company swung to an $86.3 million net loss, burdened by a massive $47.5 million legal contingency charge and acquisition costs. While management raised full-year guidance substantially—signaling high confidence in consumer demand—the transition from high-margin compounded drugs to lower-margin branded options is structurally resetting the company's earning power.
🐂 Bull Case
Rest of World revenue exploded by 1,641% YoY to $131.4 million. The successful June close of the Eucalyptus acquisition instantly gives HIMS a massive global footprint and radically expands its total addressable market.
Monthly Revenue per Average Subscriber accelerated to $92 (up 21% YoY). The strategic shift toward branded GLP-1s and higher-tier personalized treatments is successfully extracting more value per user.
🐻 Bear Case
Gross margin crashed from 76% to 64%. The pivot away from internally compounded drugs toward branded pharmaceuticals (like Wegovy/Zepbound) structurally lowers the company's gross profitability.
The company absorbed a $47.5 million legal contingency in Q2, following a $15 million charge in Q1. This unquantified regulatory/legal risk is crushing GAAP profitability and masking underlying operational leverage.
⚖️ Verdict: ⚪
Neutral. Top-line execution is flawless and the raised guidance proves momentum is accelerating. However, until the legal bleed stops and gross margins find a floor, the quality of earnings remains highly questionable.
Key Themes
Eucalyptus Acquisition Supercharges Global Scale
International expansion is officially accelerating. 'Rest of the World' revenue skyrocketed from $7.5M a year ago to $131.4M this quarter. The integration of Eucalyptus provides immediate scale across Europe and Australia. Management's long-term target of $1 billion in international revenue now looks highly credible, shifting the company away from sheer U.S. dependency.
Gross Margin Reset Underway
The margin collapse is stark: reversing from 76% in 25Q2 to 64% today. Management's strategic decision to prioritize branded weight-loss GLP-1s over compounded alternatives drives massive revenue growth but sacrifices unit economics. Investors must accept that HIMS is transitioning from a high-margin software/compounding profile to a lower-margin pharmaceutical distribution profile.
Domestic Re-Acceleration
U.S. Revenue grew 16% YoY to $621.8 million, marking an acceleration from the 'financial noise' seen in Q1. Management explicitly noted expectations for the domestic business to continue accelerating through the second half of the year, driven by cohort stacking and the stabilization of the weight-loss strategy.
Legal and Restructuring Drag Contradicts Efficiency Claims
Management touted 'meaningful efficiencies' from AI and tech investments, but the financials tell a story of ballooning overhead. General & Administrative expenses exploded to $165.4M (from $67.3M last year). This was heavily driven by a massive $47.5M legal contingency and $28.8M in acquisition costs. This pattern of 'one-time' charges (following Q1's $33M restructuring and $15M legal hit) is becoming a recurring drag on shareholder value.
AI Clinical Engine Rollout
The company is actively rebuilding its consumer experience around a 'doctor-led AI clinical engine.' While the exact financial ROI is tough to isolate, technology and development spending grew to $54.9M (+45% YoY). This platform investment is critical for handling the 2.9 million active subscribers efficiently, aiming to act as a long-term moat against legacy healthcare providers.
Regulatory Shifts Dictating Strategy
The regulatory landscape around compounded GLP-1 availability continues to dictate product mix. By shifting aggressively toward FDA-approved branded medications, HIMS is mitigating macro regulatory risk (FDA crackdowns on compounding pharmacies) but simultaneously absorbing the aforementioned gross margin hit.
Other KPIs
Reversing. FCF swung deeply negative, compared to a positive $53M in Q1. This was heavily impacted by the cash outlay for the Eucalyptus acquisition, a $35.9M cash burn from operating activities, and continued elevated capital expenditures. The balance sheet remains liquid, but the cash generation narrative is on pause.
Stable. The subscriber base grew 19% YoY. While absolute subscriber growth is solid, the real driver of the 38% revenue spike is the 21% increase in revenue per subscriber ($92/month), showing that HIMS is successfully monetizing its existing base with higher-ticket items.
Guidance
Accelerating. Raised significantly from the prior $2.8 - $3.0 billion target. The $3.2B midpoint implies a massive 36% YoY growth rate over FY25's $2.35B. This guide confirms that the integration of Eucalyptus and the domestic weight-loss rollout are expected to perform above previous internal expectations.
Decelerating margin profile. While absolute EBITDA dollars are growing, the midpoint ($300M) on $3.2B of revenue implies a 9.4% annual margin. This is a noticeable step down from the 13-14% margins achieved in FY25, explicitly reflecting the margin dilution of the new branded product mix.
Accelerating. The midpoint of $890M represents an 18% sequential increase over Q2 ($753M) and a massive ~48% YoY increase over 25Q3 ($599M). The top-line momentum is undeniable.
Stable. The midpoint of $85M yields an implied margin of roughly 9.5%, confirming that the 8% margin seen in Q2 is the new baseline reality, far below the 13%+ margins seen in the back half of last year.
Key Questions
Nature of Legal Contingencies
You recorded a massive $47.5M legal contingency this quarter on top of Q1's $15M charge. What specific regulatory or litigation events are driving these costs, and should investors view these as recurring rather than one-time?
Gross Margin Floor
With gross margins compressing to 64% due to the branded weight-loss pivot, where do you see the structural bottom for gross margins over the next 4-6 quarters?
Eucalyptus Organic Growth
International revenue surged to $131M with the close of Eucalyptus. How much of this was organic growth versus pure M&A arithmetic, and what is the timeline for the international segment to achieve positive Adjusted EBITDA?